The Vasculitis Foundation, the leading international supporter of research on vasculitis, is pleased to announce a special funding opportunity to fund research on Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg Strauss Syndrome).
EGPA is a rare systemic vasculitis predominantly affecting small-sized vessels. Main clinical characteristics of EGPA include late-onset allergic rhinitis and asthma, increased blood eosinophil count and vasculitis manifestations, some of which can be life-threatening. Mechanisms of the disease are complex and not completely elucidated, but treatment is well standardized, and the majority of patients respond well to therapy.
The award will provide up to $50,000 to support a one-year study to stimulate research that addresses scientific questions related to EGPA. The VF Research Program places a high priority on both clinical and basic scientific research into the cause, prevention, detection, treatment and cure of EGPA.
This is a special funding opportunity and applications will be considered separately from the VF’s Research Program’s annual review cycle of research grant applications.
Letters of Interest: Interested individuals/organizations should submit letters of interest no later than March 1, 2015, containing the following preliminary information:
Please submit your letter of interest to Joyce A. Kullman, VF Executive Director.
Click here to download the application.
Application deadline: April 1, 2015
Selection Process: Applications will be reviewed by a panel of VF selected experts in the areas of vasculitis. The review process will occur over a 4-week period (April – May 2015). A single award will be provided by June 2015 to the most meritorious applicant(s) that meets committee objectives.
Do you like this post or do you just want to share it with people you know?